ImmunAbs Inc.
PrivateLast Round
Grant
Jan 31, 2024
Total Funding Raised
$34.98M
Company Overview
ImmunAbs Inc. operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Grant round in January 2024.
ImmunAbs Inc. is a biotechnology company that develops novel antibody therapeutics for autoimmune diseases, diabetic retinopathy, and metabolic syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunAbs Inc. Comparables
Compare ImmunAbs Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbClon Inc. | 78% | |
| Hummingbird Bioscience | 77% | |
| Y-Biologics | 76% |
For institutional investors. Book with your work email.
ImmunAbs Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 31, 2024 | ||||
| Series B | Nov 30, 2022 | ||||
| Grant | Nov 1, 2021 | ||||
| Series A | Sep 30, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImmunAbs Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| D3 Jubilee Partners | Series B |
| Seoul Investment Partners | Series B, Series A |
| CKD Venture Capital | Series B |
| Korea Drug Development Fund | Grant |
| Alpen Route | Pre Seed |
| LogInvestment | Pre Seed |
| DS Asset Management | Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 18, 2026
Monthly visitors increased 482% MoM.
- Nov 30, 2022
$9.56M round with participation from CKD Venture Capital and Daekyo Investment.
For institutional investors. Book with your work email.
ImmunAbs Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunAbs Inc.'s valuation, stock price, and market status.
Is ImmunAbs Inc. a public or private company?
ImmunAbs Inc. is a private company.
What is the current stock price of ImmunAbs Inc.?
ImmunAbs Inc. is a private company, so its shares have no public market price. Caplight tracks ImmunAbs Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunAbs Inc. worth (valuation)?
Valuation information for ImmunAbs Inc. is not publicly available.
Can I buy ImmunAbs Inc. stock?
ImmunAbs Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunAbs Inc.'s last funding round?
ImmunAbs Inc.'s most recent funding round was Grant on January 31, 2024.
Who are the main investors in ImmunAbs Inc.?
Key investors in ImmunAbs Inc. include D3 Jubilee Partners, Seoul Investment Partners, CKD Venture Capital, Korea Drug Development Fund, Alpen Route.
Will ImmunAbs Inc. IPO soon?
No public IPO plans have been announced for ImmunAbs Inc..
How can I track ImmunAbs Inc. secondary market activity?
Caplight tracks bids, offers, and trades in ImmunAbs Inc.'s shares on secondary markets.